Trial Profile
A study assessing COVID-EIG for the treatment for severe hospitalized patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 26 Mar 2020
Price :
$35
*
At a glance
- Drugs COVID-2019 immune globulins (Equine) (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 26 Mar 2020 New trial record
- 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.